In progress

To develop an approach/device to accurately measure individual food intake (real time measurement or proxy) in group-housed mice (three to five mice). 

To develop and validate a handheld device for objective monitoring of rheumatoid arthritis (RA) progression in conscious rodents (either restrained or unrestrained).

To develop an in vitro model of the human liver that is metabolically and immunologically-competent for the routine assessment of Yellow Fever (YF) vaccine attenuation. 

To develop an in silico-based tool that reliably predicts human respiratory irritancy potential of chemicals.

To develop a data model that integrates and maps information on the relation between specific genes and specific physiology, or specific compounds and specific effects, between non-mammalian and mammalian model organisms, all with a focus on humans.

To develop reliable predictions which confidently classify mixtures of chemicals for acute oral toxicity, skin and eye irritation with a focus on relevance for human safety. These should fulfil acute GHS Classification and Labelling requirements for non-encapsulated agrochemical mixtures using existing information on components and formulations without the need for additional in vivo, and ideally in vitro, studies.

To establish a 3D retinal cell model which is physiologically-competent and predictive of human physiology for use in the development of new ophthalmology treatments.

To develop an in vitro model to recapitulate the human osteoarthritic joint that will provide a device based on a human tissue or a multiple human cell type co-culture system for research and drug development in osteoarthritis.

To develop in vitro / in silico assay(s) that can be used singly or in combination to improve risk assessment for GT products. These assays should be applicable to the assessment of a wide range of vector types (in addition to the ‘first generation’ gamma-retroviral vectors and autologous bone marrow-derived stem cells), different target tissues and modes of delivery and emerging technologies (e.g. gene editing).  

 

Subscribe to RSS - In progress